As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S.
BALTIMORE, Aug. 16, 2023 /PRNewswire/ -- Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the US. Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is a generic equivalent of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc.
QUEBEC CITY, July 11, 2023 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) announced on May 26, 2023, that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva® (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada. Lupin wishes to clarify that Tiotropium Bromide Inhalation Powder is indicated in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Indian drugmaker Lupin today said it won FDA approval for the first generic version of Spiriva, a blockbuster COPD drug from Boehringer Ingelheim.
Lupin's Generic (Tiotropium Bromide) Receives Approval in the U.S.
Global pharma major Lupin Limited (Lupin) announced that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.
Information for healthcare professionals and the public about the COVID-19 Vaccine SKYCovion
FDA Confirms Paragraph IV Patent Litigation for Tiotropium Bromide
Global pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva.
Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced the launch of a bioequivalent version of tiotropium bromide dry powder inhaler (DPI) under the brand name Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).